Company intelligence / Profile preview
C&C Research Laboratories
Suwon-si, Gyeonggi-do, South Koreacnclab.co.kr ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
C&C Research Laboratories has developed multiple first-in-class drug candidates targeting oncology and immune diseases using its CLOVER platform. Notable achievements include the discovery of STAT protein inhibitors with ongoing preclinical work on STAT3-, STAT5-, and STAT6-targeted small molecules. The company has advanced compounds such as URC102 for gout into later-stage trials via outlicensing to partners.
- Therapeutic areas
- OncologyRheumatologyImmunology
- Modalities
- Small molecule
- Industry
- Biotech
02
Drug pipeline
4 assets3 more assets in the full pipeline.
03
Partnerships
Chugai Pharmaceutical/Roche Group (historical)XtalPi
Beyond the preview
Go deeper on C&C Research Laboratories.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on C&C Research Laboratories.